Cargando…
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
Multiple myeloma (MM) is an incurable hematologic malignancy caused by the autonomous growth of malignant plasma cells. In the last decade, the introduction of novel targeted agents such as thalidomide, bortezomib, and lenalidomide has dramatically improved the clinical outcome of MM patients in bot...
Autores principales: | Wang, Jing, Guo, Hongfeng, Zhou, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459627/ https://www.ncbi.nlm.nih.gov/pubmed/26082645 http://dx.doi.org/10.2147/OTT.S65762 |
Ejemplares similares
-
Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022) -
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022) -
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
por: Merz, Maximilian, et al.
Publicado: (2020) -
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012) -
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
por: Schoenbeck, Kelly L, et al.
Publicado: (2020)